PSA velocity and doubling time in diagnosis and prognosis of prostate cancer

被引:79
|
作者
Vickers, Andrew J. [1 ]
Brewster, Simon F. [2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 307 E 63rd St,2nd Floor, New York, NY 10065 USA
[2] Churchill Hosp, Dept Urol, Oxford OX3 7LJ, England
[3] Univ Oxford, Churchill Hosp, Nuffield Dept Surg, Oxford OX3 7LJ, England
关键词
Prostatic neoplasms; Prostate specific antigen;
D O I
10.1016/j.bjmsu.2011.08.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cancer is a growth process and it is natural that we should be concerned with how the routinely used marker of prostate cancer tumour burden PSA - changes over time. Such change is measured by PSA velocity or PSA doubling time, described in general as "PSA kinetics''. However, it turns out that calculation of PSA velocity and doubling time is far from straightforward. More than 20 different methods have been proposed, and many of these give quite divergent results. There is clear evidence that PSA kinetics are critical for understanding prognosis in advanced or relapsed prostate cancer. However, PSA kinetics have no value for men with an untreated prostate: neither PSA velocity nor doubling time have any role in diagnosing prostate cancer or providing a prognosis for men before treatment. (C) 2011 British Association of Urological Surgeons. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:162 / 168
页数:7
相关论文
共 50 条
  • [1] A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer REPLY
    Vickers, Andrew J.
    Scardino, Peter T.
    Thompson, Ian M.
    Klein, Eric
    Carroll, Peter R.
    UROLOGY, 2014, 83 (03) : 597 - 598
  • [2] Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time
    Ng, Michael K.
    Van As, Nicholas
    Thomas, Karen
    Woode-Amissah, Ruth
    Horwich, Alan
    Huddart, Robert
    Khoo, Vincent
    Thompson, Alan
    Dearnaley, David
    Parker, Chris
    BJU INTERNATIONAL, 2009, 103 (07) : 872 - 876
  • [3] A Commentary on PSA Velocity and Doubling Time for Clinical Decisions in Prostate Cancer EDITORIAL COMMENT
    Loeb, Stacy
    UROLOGY, 2014, 83 (03) : 596 - 597
  • [4] Identification of High-Risk Prostate Cancer: Role of Prostate-Specific Antigen, PSA Doubling Time, and PSA velocity
    Heidenreich, Axel
    EUROPEAN UROLOGY, 2008, 54 (05) : 976 - 979
  • [5] The utility of PSA doubling time to monitor prostate cancer recurrence
    Wieder, JA
    Belldegrun, AS
    MAYO CLINIC PROCEEDINGS, 2001, 76 (06) : 571 - 572
  • [6] PSA VELOCITY PER PROSTATE VOLUME: A TOOL FOR PROSTATE CANCER DIAGNOSIS
    Benecchi, Luigi
    Loeb, Stacy
    Potenzoni, Michele
    Bocchi, Francesca
    Russo, Fabrizio
    Del Boca, Carlo
    JOURNAL OF UROLOGY, 2013, 189 (04): : E789 - E789
  • [7] PSA doubling time is not a surrogate for prostate-cancer-specific survival
    Nature Clinical Practice Oncology, 2007, 4 (2): : 69 - 69
  • [8] A charting tool for estimating the PSA doubling time in patients with prostate cancer
    Bellera, Carine A.
    Hanley, James A.
    Joseph, Lawrence
    Albertsen, Peter C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01): : 315 - 316
  • [9] Gene therapy prolongs PSA doubling time in prostate cancer patients
    Thompson, Timothy C.
    Rodriguez, Ron
    MOLECULAR THERAPY, 2007, 15 (03) : 442 - 443
  • [10] PSA doubling time is not a surrogate for prostate-cancer-specific survival
    Nature Clinical Practice Urology, 2007, 4 (3): : 118 - 118